{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:41:51Z","timestamp":1769146911528,"version":"3.49.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1023\/a:1011808701117","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T06:26:45Z","timestamp":1040624805000},"page":"403-418","source":"Crossref","is-referenced-by-count":60,"title":["Drug Treatment of Obesity"],"prefix":"10.1007","volume":"2","author":[{"given":"George A.","family":"Bray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"357719_CR1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/edrv.20.6.0383","volume":"20","author":"GA Bray","year":"1999","unstructured":"Bray GA, Greenway FL. Current and potential drugs for treatment of obesity [Review]. Endocr Rev 1999;20:805-875.","journal-title":"Endocr Rev"},{"key":"357719_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0025-7125(16)30701-5","volume":"73","author":"M Weintraub","year":"1989","unstructured":"Weintraub M, Bray GA. Drug treatment of obesity [Review]. Med Clin North Am 1989;73:237-249.","journal-title":"Med Clin North Am"},{"key":"357719_CR3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(98)22029-0","volume":"352","author":"GA. Bray","year":"1998","unstructured":"Bray GA. Obesity--A time-bomb to be defused. Lancet 1998;352:160-161.","journal-title":"Lancet"},{"key":"357719_CR4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/j.1550-8528.1999.tb00414.x","volume":"7","author":"DH Ryan","year":"1999","unstructured":"Ryan DH, Bray GA, Helmcke F et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999;7:313-322.","journal-title":"Obes Res"},{"key":"357719_CR5","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","volume":"160","author":"FG McMahon","year":"2000","unstructured":"McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension. Arch Int Med 2000;160:2185-2191.","journal-title":"Arch Int Med"},{"key":"357719_CR6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","volume":"24","author":"N Finer","year":"2000","unstructured":"Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306-313.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"357719_CR7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/oby.2000.48","volume":"8","author":"M Flechtner-Mors","year":"2000","unstructured":"Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: Four-year results. Obes Res 2000;8:399-402.","journal-title":"Obes Res"},{"key":"357719_CR8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","volume":"1","author":"JF Munro","year":"1968","unstructured":"Munro JF, MacCuish AC, Wilson EM et al. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968;1:352-354.","journal-title":"Br Med J"},{"key":"357719_CR9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1550-8528.1999.tb00709.x","volume":"7","author":"FL Greenway","year":"1999","unstructured":"Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999;7:523-531.","journal-title":"Obes Res"},{"key":"357719_CR10","first-page":"260","volume":"16","author":"A Astrup","year":"1992","unstructured":"Astrup A, Breum L, Tourbro S et al. The effect and satiety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placeo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes 1992;16:260-277.","journal-title":"Int J Obes"},{"key":"357719_CR11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/j.1550-8528.1999.tb00436.x","volume":"7","author":"CD Sjostrom","year":"1999","unstructured":"Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999;7:477-484.","journal-title":"Obes Res"},{"key":"357719_CR12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1037\/0022-006X.65.1.79","volume":"65","author":"GD Foster","year":"1997","unstructured":"Foster GD, Wadden TA, Vogt RA et al. What is a reasonable weight loss? Patients expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997;65:79-85.","journal-title":"J Consult Clin Psychol"},{"issue":"Suppl4","key":"357719_CR13","first-page":"425S","volume":"3","author":"GA. Bray","year":"1995","unstructured":"Bray GA. Evaluation of drugs for treating obesity [Review]. Obes Res 1995;3Suppl 4:425S-434S.","journal-title":"Obes Res"},{"issue":"6778","key":"357719_CR14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/35007544","volume":"404","author":"GA Bray","year":"2000","unstructured":"Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity [Review]. Nature 2000;404(6778):672-677.","journal-title":"Nature"},{"key":"357719_CR15","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","volume":"276","author":"National Task Force on the PreventionTreatment of Obesity.","year":"1996","unstructured":"National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity [Review]. JAMA 1996;276:1907-1915.","journal-title":"JAMA"},{"key":"357719_CR16","first-page":"441","volume-title":"Obesity in Perspective","author":"B. Scoville","year":"1975","unstructured":"Scoville B. Review of amphetamine-like drugs by the Food and Drug Administration: Clinical data and value judgments. In: Obesity in Perspective. Washington: Department of Health, Education, and Welfare, Publication no. 75-708, 1975:441-443."},{"key":"357719_CR17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1742-1241.1965.tb03144.x","volume":"19","author":"JJ Silverstone","year":"1965","unstructured":"Silverstone JJ, Solomon T. The long-term management of obesity in general practice. Br J Clin Pract 1965;19:395-398.","journal-title":"Br J Clin Pract"},{"key":"357719_CR18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1185\/03007997309111712","volume":"1","author":"RHG. McKay","year":"1973","unstructured":"McKay RHG. Long-term use of diethylpropion in obesity. Curr Med Res Opin 1973;1:489-493.","journal-title":"Curr Med Res Opin"},{"key":"357719_CR19","first-page":"289","volume":"16","author":"KJ Langlois","year":"1974","unstructured":"Langlois KJ, Forbes JA, Bell GW, Grant GF Jr. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. Curr Ther Res 1974;16:289-296.","journal-title":"Curr Ther Res"},{"key":"357719_CR20","first-page":"814","volume":"22","author":"H Gershberg","year":"1977","unstructured":"Gershberg H, Kane R, Hulse M, Pensgen E. Effects of diet and an anorectic drug (phentermine resin) in obese diabetics. Curr Ther Res 1977;22:814-820.","journal-title":"Curr Ther Res"},{"key":"357719_CR21","first-page":"851","volume":"218","author":"CJ Campbell","year":"1977","unstructured":"Campbell CJ, Bhalla IP, Steel JM, Duncan LJP. A controlled trial of phentermine in obese diabetic patients. Practitioner 1977;218:851-855.","journal-title":"Practitioner"},{"key":"357719_CR22","first-page":"231","volume":"225","author":"RA Williams","year":"1981","unstructured":"Williams RA, Foulsham BM. Weight reduction in osteoarthritis using phentermine. Practitioner 1981;225:231-232.","journal-title":"Practitioner"},{"key":"357719_CR23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/clpt.1991.144","volume":"50","author":"M Weintraub","year":"1991","unstructured":"Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: A dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-337.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl2","key":"357719_CR24","first-page":"40","volume":"19","author":"SP Jones","year":"1995","unstructured":"Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine. Int J Obes 1995;19(Suppl 2):40.","journal-title":"Int J Obes"},{"key":"357719_CR25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/j.1550-8528.1996.tb00544.x","volume":"4","author":"GA Bray","year":"1996","unstructured":"Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. 1996 A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-270.","journal-title":"Obes Res"},{"key":"357719_CR26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.ijo.0800540","volume":"22","author":"C Hanotin","year":"1998","unstructured":"Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study. Int J Obes Relat Metab Disord 1998;22:32-58.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"357719_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","volume":"7","author":"GA Bray","year":"1999","unstructured":"Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels CM, Mendels J, Ryan D, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-198.","journal-title":"Obes Res"},{"key":"357719_CR28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","volume":"106","author":"M Apfelbaum","year":"1999","unstructured":"Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184.","journal-title":"Am J Med"},{"key":"357719_CR29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.ijo.0801098","volume":"24","author":"G Fanghanel","year":"2000","unstructured":"Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes 2000;24:144-150.","journal-title":"Int J Obes"},{"key":"357719_CR30","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"WPT James","year":"2000","unstructured":"James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WHM, van Gaal L, for the STORM study group. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet 2000;356:2119-2125.","journal-title":"Lancet"},{"key":"357719_CR31","doi-asserted-by":"crossref","unstructured":"Sramek, JJ, Seiowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by \u03b2-adrenergic blocking agents: A placebo-controlled, double-blind, randomized trial. Am J Hypertension 2001 [in press].","DOI":"10.1038\/sj.jhh.1001299"},{"key":"357719_CR32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","volume":"2","author":"N Finer","year":"2000","unstructured":"Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind placebo-controlled study. Diab Obes Metab 2000;2:105-112.","journal-title":"Diab Obes Metab"},{"key":"357719_CR33","first-page":"1","volume":"2","author":"Fujioka K, Seaton TB, Rowe E, Jelinek CA, RaskinP, Lebovitz HE, Weinstein SP,the Sibutramine\/Diabetes clinical study group.","year":"2000","unstructured":"Fujioka K, Seaton TB, Rowe E, Jelinek CA, RaskinP, Lebovitz HE, Weinstein SP, and the Sibutramine\/Diabetes clinical study group. Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese type 2 diabetes mellitus. Diab Obes Metab 2000;2:1-13.","journal-title":"Diab Obes Metab"},{"key":"357719_CR34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.161.2.218","volume":"161","author":"RA Wadden","year":"2001","unstructured":"Wadden RA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg CM. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med 2001;161:218-227.","journal-title":"Arch Intern Med"},{"issue":"25","key":"357719_CR35","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1056\/NEJM200012213432501","volume":"343","author":"WN Kernan","year":"2000","unstructured":"Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):1826-1832.","journal-title":"N Engl J Med"},{"key":"357719_CR36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","volume":"51","author":"M. Weintraub","year":"1992","unstructured":"Weintraub M. Long term weight control: The National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51:581-585.","journal-title":"Clin Pharmacol Ther"},{"key":"357719_CR37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.","journal-title":"N Engl J Med"},{"key":"357719_CR38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/0003-4819-134-4-200102200-00008","volume":"134","author":"ST Mast","year":"2001","unstructured":"Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261-266.","journal-title":"Ann Intern Med"},{"key":"357719_CR39","unstructured":"Greenway FL. Buproprion SR significantly enhances weight loss when used with a moderate-intensity lifestyle intervention [Abstract]. Diabetes 2001 (in press)."},{"issue":"Suppl8","key":"357719_CR40","first-page":"98","volume":"38","author":"Rosenfeld WE, Kanner A, Jacobson N, Kretschner P,the PADS Investigator Group.","year":"1997","unstructured":"Rosenfeld WE, Kanner A, Jacobson N, Kretschner P, and the PADS Investigator Group. Topiramate and concomitant weight loss. Epilepsia 1997;38(Suppl 8):98.","journal-title":"Epilepsia"},{"key":"357719_CR41","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/43185","volume":"387","author":"CT Montague","year":"1997","unstructured":"Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-908.","journal-title":"Nature"},{"key":"357719_CR42","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJM199909163411204","volume":"341","author":"IS Farooqi","year":"1999","unstructured":"Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-884.","journal-title":"N Engl J Med"},{"key":"357719_CR43","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","volume":"282","author":"SB Heymsfield","year":"1999","unstructured":"Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-1575.","journal-title":"JAMA"},{"key":"357719_CR44","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jcem.85.11.6955","volume":"85","author":"CJ Huckshorn","year":"2000","unstructured":"Huckshorn CJ, Saris WH, Westerterp-Plantenga et al. Weekly subcutaneous pegylated recombinant native human leptin (PEGOB) administration in obese men. J Clin Endocrinol Metab 2000;85:4003-4009.","journal-title":"J Clin Endocrinol Metab"},{"key":"357719_CR45","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1073\/pnas.061034298","volume":"98","author":"PD Lambert","year":"2001","unstructured":"Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Nat Acad Sci 2001;98:4652-4657.","journal-title":"Proc Nat Acad Sci"},{"key":"357719_CR46","unstructured":"Guler HP, Ettinger TW, Littlejohn SL, Schwartz SL, Weiss SL, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Acheson A, Heyman ER, Dark CL, Vicary C. Axokine causes significant weight loss in severely and morbidly obese subjects. Int J Obes 2001 (in press)."},{"key":"357719_CR47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","volume":"101","author":"A Flint","year":"1998","unstructured":"Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520.","journal-title":"J Clin Invest"},{"key":"357719_CR48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/oby.2000.38","volume":"8","author":"KA Al-Barazanji","year":"2000","unstructured":"Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa\/fa) Zucker rats. Obes Res 2000;8:317-323.","journal-title":"Obes Res"},{"issue":"6778","key":"357719_CR49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","volume":"404","author":"MW Schwartz","year":"2000","unstructured":"Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake [Review]. Nature. 2000;404(6778):661-671.","journal-title":"Nature"},{"issue":"5487","key":"357719_CR50","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1126\/science.289.5487.2122","volume":"289","author":"JC Bruning","year":"2000","unstructured":"Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289(5487):2122-2125.","journal-title":"Science"},{"issue":"2","key":"357719_CR51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0022-3476(99)70017-X","volume":"135","author":"RH Lustig","year":"1999","unstructured":"Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, Li H, Hudson MM, Heideman RL, Kun LE. Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 1999;135(2 Pt 1):162-168.","journal-title":"J Pediatr"},{"key":"357719_CR52","doi-asserted-by":"crossref","first-page":"309S","DOI":"10.1093\/ajcn\/55.1.309s","volume":"5","author":"JB Hauptmann","year":"1992","unstructured":"Hauptmann JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992;5:309S-313S.","journal-title":"Am J Clin Nutr"},{"key":"357719_CR53","first-page":"221","volume":"19","author":"ML Drent","year":"1995","unstructured":"Drent ML, Larsson I, William-Olsson T, Quadde F, Czubayko F, von Bergmann K, Strobel W, Sjostrom L, van der Veen EA. Orlistat (Ro18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study. Int J Obes 1995;19:221-226.","journal-title":"Int J Obes"},{"issue":"3","key":"357719_CR54","first-page":"S24","volume":"21","author":"WPT James","year":"1997","unstructured":"James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. 1997;21(3):S24-S30.","journal-title":"A one-year trial to assess the value of orlistat in the management of obesity"},{"key":"357719_CR55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002280050433","volume":"54","author":"LF Van Gaal","year":"1998","unstructured":"Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity--A 6-month dose-ranging study. Eur J Clin Pharm 1998;54:125-132.","journal-title":"Eur J Clin Pharm"},{"key":"357719_CR56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-172.","journal-title":"Lancet"},{"key":"357719_CR57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","volume":"281","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Long-term weight control and risk factor reduction in obese subjects treated with orlistat, a lipase inhibitor. JAMA 1999;281:235-242.","journal-title":"JAMA"},{"key":"357719_CR58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","volume":"24","author":"N Finer","year":"2000","unstructured":"Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306-313.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"357719_CR59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","volume":"8","author":"S Rossner","year":"2000","unstructured":"Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G, on behalf of the European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular riskfactors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61.","journal-title":"Obes Res"},{"key":"357719_CR60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","volume":"9","author":"J Hauptmann","year":"2000","unstructured":"Hauptmann J, Lucas C, Boldrin MN, Collins H, Segal KR, for the Orlistat Primary Care Study Group. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167.","journal-title":"Arch Fam Med"},{"key":"357719_CR61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","volume":"248","author":"F Lindgarde","year":"2000","unstructured":"Lindgarde F, on behalf of the Orlistat Swedish Multimorbidity study group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity study. J Intern Med 2000;248:245-254.","journal-title":"J Intern Med"},{"key":"357719_CR62","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","volume":"69","author":"JO Hill","year":"1999","unstructured":"Hill JO, Hauptmann, J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study. Am J Clin Nutr 1999;69:1108-1116.","journal-title":"Am J Clin Nutr"},{"key":"357719_CR63","first-page":"S623","volume":"3","author":"ML Drent","year":"1995","unstructured":"Drent ML, van der Veen EA. First clinical studies with orlistat: A short review. Obes Res 1995;3:S623-S625.","journal-title":"Obes Res"},{"key":"357719_CR64","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","volume":"21","author":"P Hollander","year":"1998","unstructured":"Hollander P, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of Orlistat in the treatment of obese patients with type 2 diabetes. Diab Care 1998;21:1288-1294.","journal-title":"Diab Care"},{"key":"357719_CR65","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","volume":"160","author":"SB Heymsfield","year":"2000","unstructured":"Heymsfield, SB, Segal KR, Hauptman, J, Lucas CP, Boldrin MN, Rissanen A, JPH Wilding Sjostrom L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 Diabetes in obese adults. Arch Intern Med 2000;160:1321-1326.","journal-title":"Arch Intern Med"},{"key":"357719_CR66","doi-asserted-by":"crossref","unstructured":"Reaven G, Segal K, Haputman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with Syndrome X. Am J Med 2001 [in press].","DOI":"10.1016\/S0002-9149(00)01521-6"},{"key":"357719_CR67","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00191901","volume":"46","author":"S Tonstad","year":"1994","unstructured":"Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E. The effects of gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994;46:405-410.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl1","key":"357719_CR68","first-page":"43S","volume":"8","author":"B Mittendorfer","year":"2000","unstructured":"Mittendorfer B, Ostlund R, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2000;8(Suppl 1):43S.","journal-title":"Obes Res"},{"issue":"6","key":"357719_CR69","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","volume":"8","author":"TA Wadden","year":"2000","unstructured":"Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial. Obes Res 2000;8(6):431-437.","journal-title":"Obes Res"},{"issue":"5","key":"357719_CR70","first-page":"E507","volume":"248","author":"A Astrup","year":"1985","unstructured":"Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol. 1985;248(5 Pt 1):E507-E515.","journal-title":"Am J Physiol."},{"issue":"Suppl4","key":"357719_CR71","first-page":"537S","volume":"3","author":"A Astrup","year":"1995","unstructured":"Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists [Review]. Obes Res 1995;3Suppl 4:537S-540S.","journal-title":"Obes Res"},{"issue":"Suppl1","key":"357719_CR72","first-page":"44S","volume":"8","author":"TM Larsen","year":"2000","unstructured":"Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WHM, Astrup A. No thermogenic effect after 28 days treatment with L-796,568, a novel beta-3-adrenoceptor, in obese men. Obes Res 2000;8(Suppl 1):44S.","journal-title":"Obes Res"},{"key":"357719_CR73","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/jama.280.18.1596","volume":"280","author":"SB Heymsfield","year":"1998","unstructured":"Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: A randomized controlled trial. JAMA 1998;280:1596-1600.","journal-title":"JAMA"},{"issue":"Suppl1","key":"357719_CR74","first-page":"43S","volume":"8","author":"R Guerciolini","year":"2000","unstructured":"Guerciolini R, Radu-Radulescu L, Boldrin M, Moore R. Fecal fat excretion induced by treatment with orlistat or chitosan: A 3-week randomized crossover design study. Obes Res 2000;8(Suppl 1):43S.","journal-title":"Obes Res"},{"issue":"5","key":"357719_CR75","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.ejcn.1600733","volume":"53","author":"MH Pittler","year":"1999","unstructured":"Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999;53(5):379-381.","journal-title":"Eur J Clin Nutr"},{"key":"357719_CR76","unstructured":"Nasser JA et al. 1999. Efficacy trial for weight loss of an herbal supplement of Ma Huang and guarana. FASEB J 1999;13(5)."},{"issue":"1","key":"357719_CR77","first-page":"68","volume":"9","author":"CN Boozer","year":"2001","unstructured":"Boozer CN, Daly PA, Blanchard D, Nasser JA, Solomon JL, Homel P. Herbal ephedra\/caffeine for weight loss: A 6-month safety and efficacy trial [Abstract]. Obes Res 2001;9(1):68.","journal-title":"Obes Res"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1011808701117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1011808701117\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1011808701117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T09:33:44Z","timestamp":1754472824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1011808701117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["357719"],"URL":"https:\/\/doi.org\/10.1023\/a:1011808701117","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10]]}}}